Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.

Conclusion: Empagliflozin is cost-effective treatment versus glimepiride applying a threshold of $30,290 (CNY212,676). PMID: 33576249 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research